LEADER 01401nam  2200421   450 
001 9910715165303321
005 20201214153915.0
035   $a(CKB)5470000002508360
035   $a(OCoLC)1226746120
035   $a(EXLCZ)995470000002508360
100   $a20201214d2020      ua             0
101 0 $aeng
135   $aur|||||||||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 00$aCounterfeit controlled prescription drug availability in Pennsylvania and Delaware
210  1$a[Washington, D.C.] :$cDrug Enforcement Administration, Strategic Intelligence Section,$d2020.
215   $a1 online resource (8 pages) $ccolor illustrations, color maps
225 1 $aDEA intelligence report ;$vDEA-PHL-DIR-035-20
300   $a"September 2020."
300   $aUnclassified.
606   $aDrug adulteration
606   $aProduct counterfeiting$zPennsylvania
606   $aProduct counterfeiting$zDelaware
606   $aFentanyl$zPennsylvania
606   $aFentanyl$zDelaware
615  0$aDrug adulteration.
615  0$aProduct counterfeiting
615  0$aProduct counterfeiting
615  0$aFentanyl
615  0$aFentanyl
801  0$bGPO
801  1$bGPO
906   $aBOOK
912   $a9910715165303321
996   $aCounterfeit controlled prescription drug availability in Pennsylvania and Delaware$93329210
997   $aUNINA